Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,718 questions · 1,762 findings · 100 reviews · Headline outcomes only

No studies found 507 · 28.8%GRADE not reported 115 · 6.5%Very low 556 · 31.6%Low 444 · 25.2%Moderate 114 · 6.5%High 26 · 1.5%

Antipsychotics vs placebo or another comparator drug/dose

Repetition of SH at six months (low dose fluphenazine vs. ultra low dose fluphenazine) · adults who engage in SH

It is very uncertain whether antipsychotics changes repetition of SH at six months (low dose fluphenazine vs. ultra low… compared with placebo or another comparator drug/dose (very low certainty).

1 finding from 1 review

Propranolol vs placebo

Treatment efficacy CAPS, CIDI · adult participants (18 years and older) who have been exposed to any traumatic events, but who did not meet the diagnostic criteria for…

Propranolol showed no clear difference in treatment efficacy CAPS, CIDI compared with placebo (low certainty).

1 finding from 1 review

Hydrocortisone vs placebo

Treatment efficacy CAPS, SCID‐IV, PTSS‐10Q‐I · adult participants (18 years and older) who have been exposed to any traumatic events, but who did not meet the diagnostic criteria for…

Hydrocortisone probably leads to lower treatment efficacy CAPS, SCID‐IV, PTSS‐10Q‐I compared with placebo (moderate certainty).

1 finding from 1 review

Antihypertensive drug class vs placebo

Angiotensin receptor blocker (any dose) Mean duration of 4 weeks · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
2 findings from 1 review

Intervention not reported

Angiotensin receptor blocker (high‐ versus medium‐dose) · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

Angiotensin receptor blocker (medium‐ versus low‐dose) · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

High‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

High‐ versus medium‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

Medium‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

Angiotensin‐converting enzyme inhibitor · children (from 1 to 18 years of age) with hypertension from primary or secondary causes

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

High‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review